Latest Annual General Meeting News

Aurelia Metals has kicked off FY26 with robust production and cost management, driven by the ahead-of-schedule ramp-up at its Federation mine and promising progress at Great Cobar.

Cleanaway Waste Management faced a challenging FY25 with multiple fatalities prompting a safety overhaul, yet reported robust financial growth and reaffirmed FY26 guidance. Strategic acquisitions and operational improvements signal a determined path forward.

Freehill Mining Limited has increased its capital raising to $540,000 through a share placement and free-attaching options, aiming to support its processing operations in Chile and strengthen working capital.

Morella Corporation has locked in A$1.4 million in convertible note funding from key shareholders and directors, strengthening its financial position to advance critical minerals exploration and acquisitions.

Alligator Energy Limited has released its comprehensive company constitution, detailing governance, shareholder rights, and director responsibilities under Australian law and ASX rules. This foundational document sets the framework for the company’s operations and compliance.

Aurumin Limited has obtained ASIC approval to extend its 2025 AGM deadline, aligning with the proposed acquisition by Brightstar Resources. This move sets the stage for a significant ownership change pending shareholder approval.

Chalice Mining is progressing its Gonneville Project Pre-Feasibility Study on schedule for November 2025 completion, fully funded and targeting a Final Investment Decision by late 2027 as palladium prices hit a two-year high.

Southern Palladium has raised A$20 million through a strategic share placement to accelerate its Bengwenyama PGM project, positioning the company for key milestones including a Final Investment Decision in 2026.

European Lithium Limited has launched a replacement options offer for holders of 205 million expiring options, with directors committing to fully participate and underwrite the offer pending shareholder approval at the upcoming AGM.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

AdAlta Limited has raised up to A$1.1 million through a private placement, boosting its war chest to advance innovative cellular immunotherapy projects targeting solid cancers.